Breye Therapeutics (Breye), a Danish clinical-stage biopharmaceutical company developing oral therapeutics for the early treatment of retinal diseases, has closed an oversubscribed €67.5 million Series A financing…
Denmark’s Breye Therapeutics raises €67.5 million to advance oral therapies for early treatment of retinal diseases
What they do:
Robots that automate the everyday tasks of microbiologists.
Quick facts:
HQ: Copenhagen, Denmark
What they do:
Unlocking the power of biotech with modern software for modern science
Quick facts:
HQ: San Francisco, CA, United States
What they do:
We make robots for biologists.
Quick facts:
HQ: New York, NY, United States
What they do:
Decarbonizing the chemicals industry.
Quick facts:
HQ: Houston, TX, United States
What they do:
Artificial intelligence for drug discovery.
Quick facts:
HQ: San Francisco, CA, United States
Funding:
$19.8M · Equity · Mar 2026
What they do:
Unleash the potential of genomic medicine using AI
Quick facts:
Funding:
€23.2M · Series B · Oct 2026
Breye Therapeutics (Breye), a Danish clinical-stage biopharmaceutical company developing oral therapeutics for the early treatment of retinal diseases, has closed an oversubscribed €67.5 million Series A financing…
Denmark
Latest round: €67.5M Series A (Oct 2026).
Similar startups: Reshape Biotech, Benchling, and Opentrons.